Evidence map›Paper›PMID 40595931›Full record

ArticleScientific reports2025

Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.

Aparna Ganesan, Anttoni Korkiakoski, Simona Adamusová, Anna Musku, Tuula Rantasalo, Nea Laine, Emma Andersson, Emerik Osterlund, Ali Ovissi, Päivi Halonen and 13 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Aparna Ganesan *Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland. aparna.ganesan@helsinki.fi.ORCID http://orcid.org/0009-0007-7574-6770
Anttoni Korkiakoski *Genomill Health Inc, Turku, Finland.ORCID http://orcid.org/0009-0006-1782-5422
Simona Adamusová *Genomill Health Inc, Turku, Finland.ORCID http://orcid.org/0009-0003-6997-1112
Anna MuskuGenomill Health Inc, Turku, Finland.
Tuula RantasaloGenomill Health Inc, Turku, Finland.
Nea LaineGenomill Health Inc, Turku, Finland.ORCID http://orcid.org/0009-0006-9376-7287
Emma AnderssonDepartment of Genetics, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3986-9892
Emerik OsterlundDepartment of Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-0973-6332
Ali OvissiDepartment of Radiology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Päivi HalonenDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-9760-0840
Tatu HirvonenGenomill Health Inc, Turku, Finland.ORCID http://orcid.org/0009-0003-4134-4686
Jorma KimGenomill Health Inc, Turku, Finland.ORCID http://orcid.org/0000-0002-6699-5616
Jukka LaineGenomill Health Inc, Turku, Finland.ORCID http://orcid.org/0000-0003-4330-0030
Antti SilvoniemiDepartment of Oncology, Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0001-9655-1410
Heikki MinnDepartment of Oncology, Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-5878-4333
Juuso BlomsterGenomill Health Inc, Turku, Finland.
Anna-Kaisa AnttonenDepartment of Genetics, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-9749-7767
Soili KytöläDepartment of Genetics, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-4477-0942
Pia OsterlundDepartment of Oncology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-7124-3515
Juha-Pekka PursiheimoGenomill Health Inc, Turku, Finland.ORCID http://orcid.org/0000-0001-5161-8570
Pirjo NummelaApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-2768-8816
Manu TamminenGenomill Health Inc, Turku, Finland. manu@genomill.com.ORCID http://orcid.org/0000-0001-5891-7653
Ari RistimäkiApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-5373-9234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, often presenting at an advanced stage with significant molecular heterogeneity. This is the first study to evaluate the performance of a novel next-generation sequencing (NGS)-based Bridge Capture technology for mutation profiling and minimal residual disease detection in circulating tumor (ct)DNA from metastatic colorectal cancer (mCRC) patients. Its performance was compared to those of droplet digital PCR (ddPCR), Ion AmpliSeq Cancer Hotspot Panel v2, and Idylla ctKRAS Mutation Assay. Eighty serial plasma samples from ten mCRC patients were analyzed by Bridge Capture and ddPCR, demonstrating a very strong correlation in variant allele frequency (VAF) values (r

Indexed as

Colorectal NeoplasmsHigh-Throughput Nucleotide SequencingMutationBiomarkers, TumorCirculating Tumor DNADNA Mutational AnalysisFemaleGene FrequencyHumansLiquid BiopsyMaleNeoplasm MetastasisPolymerase Chain ReactionBiomarkers, TumorCirculating Tumor DNABridge CapturecfDNAColorectal cancerctDNAddPCRNGS

Identifiers

PMID40595931
PMCPMC12218867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.